| Reduced lung-cancer mortality with volume CT screening in a randomized trial HJ de Koning, CM van Der Aalst, PA de Jong, ET Scholten, K Nackaerts, ... New England journal of medicine 382 (6), 503-513, 2020 | 2330 | 2020 |
| Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening N Horeweg, J van Rosmalen, MA Heuvelmans, CM van der Aalst, ... The Lancet Oncology 15 (12), 1332-1341, 2014 | 534 | 2014 |
| Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the US Preventive Services Task Force HJ De Koning, R Meza, SK Plevritis, K Ten Haaf, VN Munshi, J Jeon, ... Annals of internal medicine 160 (5), 311-320, 2014 | 518 | 2014 |
| Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers N Horeweg, ET Scholten, PA de Jong, CM van der Aalst, C Weenink, ... The Lancet Oncology 15 (12), 1342-1350, 2014 | 396 | 2014 |
| PL02. 05 effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial H De Koning, C Van Der Aalst, K Ten Haaf, M Oudkerk Journal of Thoracic Oncology 13 (10), S185, 2018 | 310 | 2018 |
| Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval U Yousaf-Khan, C van der Aalst, PA de Jong, M Heuvelmans, E Scholten, ... Thorax 72 (1), 48-56, 2017 | 276 | 2017 |
| Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study K Ten Haaf, J Jeon, MC Tammemägi, SS Han, CY Kong, SK Plevritis, ... PLoS medicine 14 (4), e1002277, 2017 | 273 | 2017 |
| Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force R Meza, J Jeon, I Toumazis, K Ten Haaf, P Cao, M Bastani, SS Han, ... Jama 325 (10), 988-997, 2021 | 246 | 2021 |
| Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial JE Walter, MA Heuvelmans, PA de Jong, R Vliegenthart, PMA van Ooijen, ... The Lancet Oncology 17 (7), 907-916, 2016 | 234 | 2016 |
| Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario, Canada K Ten Haaf, MC Tammemägi, SJ Bondy, CM van der Aalst, S Gu, ... PLoS medicine 14 (2), e1002225, 2017 | 144 | 2017 |
| Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials K Ten Haaf, J van Rosmalen, HJ de Koning Cancer Epidemiology, Biomarkers & Prevention 24 (1), 154-161, 2015 | 115 | 2015 |
| Cost-effectiveness analysis of lung cancer screening in the United States: a comparative modeling study SD Criss, P Cao, M Bastani, K Ten Haaf, Y Chen, DF Sheehan, EF Blom, ... Annals of internal medicine 171 (11), 796-804, 2019 | 107 | 2019 |
| A comparative modeling analysis of risk-based lung cancer screening strategies K Ten Haaf, M Bastani, P Cao, J Jeon, I Toumazis, SS Han, SK Plevritis, ... JNCI: Journal of the National Cancer Institute 112 (5), 466-479, 2020 | 93 | 2020 |
| Development and validation of a multivariable lung cancer risk prediction model that includes low-dose computed tomography screening results: a secondary analysis of data from … MC Tammemägi, K Ten Haaf, I Toumazis, CY Kong, SS Han, J Jeon, ... JAMA network open 2 (3), e190204-e190204, 2019 | 90 | 2019 |
| Lung cancer screening: latest developments and unanswered questions CM van der Aalst, K Ten Haaf, HJ de Koning The Lancet Respiratory Medicine 4 (9), 749-761, 2016 | 90 | 2016 |
| Disparities in receiving guideline-concordant treatment for lung cancer in the United States EF Blom, K Ten Haaf, DA Arenberg, HJ de Koning Annals of the American Thoracic Society 17 (2), 186-194, 2020 | 87 | 2020 |
| Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials R Meza, K ten Haaf, CY Kong, A Erdogan, WC Black, MC Tammemagi, ... Cancer 120 (11), 1713-1724, 2014 | 84 | 2014 |
| Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking—a modelling study Y Tomonaga, K Ten Haaf, T Frauenfelder, M Kohler, RD Kouyos, ... Lung Cancer 121, 61-69, 2018 | 69 | 2018 |
| Risk stratification based on screening history: the NELSON lung cancer screening study U Yousaf-Khan, C Van Der Aalst, PA De Jong, M Heuvelmans, E Scholten, ... Thorax 72 (9), 819-824, 2017 | 66 | 2017 |
| Disparities of national lung cancer screening guidelines in the US population SS Han, E Chow, K Ten Haaf, I Toumazis, P Cao, M Bastani, ... JNCI: Journal of the National Cancer Institute 112 (11), 1136-1142, 2020 | 54 | 2020 |
